Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.41 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.56 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.50 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL2054349 | 1.00 | TSHR (0.56) | TSHRTP53EGLN1EGLN3ALDH1A1 | |
| Benzoquinone SCHEMBL31055608 | 0.79 | ALDH1A1 (0.67) | TSHRTP53ALDH1A1BCHEPOLB | |
| Benzoquinone SCHEMBL27519977 | 0.79 | ALDH1A1 (0.67) | TSHRTP53ALDH1A1BCHEPOLB | |
| Benzoquinone SCHEMBL28211057 | 0.79 | TDP1 (0.80) | TP53ALDH1A1BCHEPOLBMAOA | |
| Benzoquinone SCHEMBL8966070 | 0.79 | TDP1 (0.80) | TP53ALDH1A1BCHEPOLBMAOA | |
| Benzoquinone SCHEMBL8619522 | 0.79 | LMNA (0.59) | TSHRTP53EGLN1EGLN3ALDH1A1 | |
| Maleic Acid SCHEMBL27583410 | 0.75 | TSHR (0.82) | TSHRTP53EGLN1EGLN3ALDH1A1 | |
| Maleic Acid SCHEMBL2046430 | 0.75 | TSHR (1.00) | TSHRTP53EGLN1EGLN3ALDH1A1 | |
| Fumaric Acid SCHEMBL3998225 | 0.75 | — | — | |
| Maleic Acid SCHEMBL20487516 | 0.75 | TSHR (1.00) | TSHRTP53EGLN1EGLN3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278909-B2 | Amide-extended crosslinking compounds and methods for use thereof | DESIGNER MOLECULES, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-8637611-B2 | Amide-extended crosslinking compounds and methods for use thereof | DESIGNER MOLECULES, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130338313-A1 | AMIDE-EXTENDED CROSSLINKING COMPOUNDS AND METHODS FOR USE THEREOF | DESIGNER MOLECULES, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-20110152466-A1 | AMIDE-EXTENDED CROSSLINKING COMPOUNDS AND METHODS FOR USE THEREOF | DESIGNER MOLECULES, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| WO-2010019832-A2 | AMIDE-EXTENDED CROSSLINKING COMPOUNDS AND METHODS FOR USE THEREOF | DESIGNER MOLECULES, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152466-A1 | AMIDE-EXTENDED CROSSLINKING COMPOUNDS AND METHODS FOR USE THEREOF | ACMSD, AAAS, NAAA | KMT2A 78/4885DPP4 3770/4885TSHR 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.